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A B S T R A C T
The complex pathophysiology of brain disorders and the diﬃculty of delivering therapeutic agents to the brain
remain major obstacles in the research and development of new therapeutic methods for brain disorders.
Therefore, delivering existing therapeutic agents to the central nervous system is expected to provide beneﬁts in
various diseases. In this study, we investigated whether inhaled central nervous system drugs reached the brain
and aﬀected mouse behaviour. Dizocilpine (MK-801), which increases locomotor activity in mice, was mainly
used to study this hypothesis. First, we administered MK-801, an N-methyl-D-aspartate receptor antagonist, to
mice via inhalation and examined whether it induced excessive activity similar to that observed after in-
traperitoneal administration. We also examined the time- and dose-dependency of drug induced changes in
mouse behaviour after MK-801 inhalation. Next, we investigated whether inhalation of scopolamine, pento-
barbital, and imipramine also aﬀected mouse behaviour. Mice that inhaled MK-801 showed MK-801–induced
hyperactivity similar to that observed following intraperitoneal administration. Furthermore, the extent of ac-
tivity changed in a time- and dose-dependent manner after MK-801 inhalation. Inhalation of pentobarbital,
scopolamine, and imipramine also changed mouse behaviour. These results demonstrate that inhalation of MK-
801 exerts eﬀects similar to those achieved with intraperitoneal and oral administration in mice. Thus, central
nervous system agonists can reach the brain eﬃciently via inhalation. This ﬁnding may facilitate the develop-
ment of improved therapies for brain disorders.
1. Introduction
Disorders of the central nervous system (CNS) represent a sub-
stantial emotional, economic, and social burden for patients, their fa-
milies, and society. Despite intensive research eﬀorts, there remains a
great unmet need for therapeutic agents in many such disorders. The
major obstacles in research and development of new therapeutic agents
for the brain are related to the complex pathophysiology of brain da-
mage, the diﬃculty of brain entry for small and large drugs, and the
risk, complexity, and cost of the clinical trials required for regulatory
approval [1]. Therefore, delivery of existing therapeutic agents to the
CNS is expected be more beneﬁcial for various CNS disorders [2].
Under normal circumstances, the blood-brain barrier (BBB) plays an
important role in protecting the delicate environment of the brain.
However, during attempts to introduce exogenous therapeutic agents
into the CNS, the BBB prevents 98% of small and large molecules from
reaching their intended targets. This lack of access to the brain is a
major barrier to drug development for CNS disorders [3]. Even if some
drugs can penetrate the BBB, additional challenges remain. Many drugs
undergo degradation in the gastrointestinal tract and metabolisation in
the liver limit the levels of numerous drugs in the blood. Increasing oral
doses to compensate for limited brain access can cause unacceptable
gastrointestinal or systemic adverse events. Although injections may
appear to be an obvious alternative route for introducing drugs into the
blood, they can cause pain and scar tissue in cases requiring frequent
dosing and needle phobia in children. Thus, injections remain an
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impractical and unattractive delivery route in many respects. Therefore,
the demand for needle-free drug delivery technology is increasing.
One novel approach to addressing this problem is to non-invasively
bypass the BBB. Intranasal administration allows drugs to bypass sys-
temic circulation and has the potential to deliver drugs directly to the
brain [4,5]. Direct delivery in this manner reduces the potential for side
eﬀects and can increase the eﬃcacy of neurotherapeutics [6]. Thus,
nasal drug delivery is currently recognised as a very promising route for
the delivery of therapeutic compounds, including biopharmaceuticals.
The existing methods for nasal administration require the use of a
dedicated device to administer the liquid containing the drug [7,8]. In
this study, we examined whether it is possible to deliver a drug to the
brain in a manner similar to inhalation of essential oils in aromatherapy
without using specialised equipment. Inhalation is the most common
method of using substances and is the shortest path to the brain, with
almost instantaneous eﬀects. Smoking is a good example of the eﬀects
of inhalation. The smoke enters the lungs where it is immediately ab-
sorbed into the bloodstream and travels to the brain. Because breathing
is an intrinsic function, inhaled delivery of drugs oﬀers an intriguing
advantage over intravenous injection. In healthy adults, more than
12,000 L of air pass through the nose daily [9]. In fact, inhalation is also
the classic method for administering both therapeutic agents and toxic
narcotics [10]. However, despite the perceived usefulness of rapid-
acting delivery, delivery by inhalation is limited to pulmonary delivery
for the treatment of lung-related diseases such as asthma, chronic ob-
structive pulmonary disease, cystic ﬁbrosis, and respiratory infections.
Dizocilpine (MK-801) is a non-competitive N-methyl-D-aspartate
(NMDA) receptor antagonist with a low molecular weight, and
blockade of glutamatergic transmission by MK-801 induces robust and
dose-dependent increases in locomotor activity [11]. Intraperitoneal
administration of MK-801 causes schizophrenia-like behavioural and
metabolic changes in the animal's brain [12,13]. Therefore, in-
traperitoneal administration of MK-801 has been used in many ex-
periments to produce an animal model of schizophrenia [14–17].
However, none of the previous studies have investigated whether in-
haled MK-801 reaches the brain and exerts its eﬀects.
We started our experiments by using MK-801 to conﬁrm the eﬀects
of inhalation of locomotor stimulant. In this study, we used a nebuliser
for inhalational administration of MK-801 to the mice. Inhalation using
a nebuliser has long been used to deliver therapeutic agents to the
airways and lungs. The nebulisation process is identical to the process
by which essential oils are converted into ﬁne air particles and inhaled
in aromatherapy. Inhalation of essential oils is said to stimulate the
brain to transmit signals through the olfactory system and release
neurotransmitters (e.g. serotonin, noradrenaline, dopamine, or en-
docannabinoids) that modulate nociceptive transmission. However,
studies on the cellular and molecular mechanisms underlying these
eﬀects are lacking. It is expected that this research will also provide an
opportunity to elucidate the mechanism of action of essential oils by
inhalation.
The purpose of this study was to clarify whether administration of
the CNS agonist MK-801 via inhalation aﬀects the CNS in mice and
inﬂuences mouse behaviour in the same way as other administration
methods. The results of this study will indicate the potential of in-
halation as a new method for CNS agonists to access the brain and
elucidate the mechanism by which nasally inhaled molecules aﬀect the
CNS.
2. Materials and methods
2.1. Animals
We used 15-week-old male mice (C57BL/6) for the experiments. We
purchased the animals from Charles River Laboratories (Kanagawa,
Japan) and housed them in cages with food and water provided ad li-
bitum under a 12-h light/dark cycle at 23 °C – 26 °C. We made every
eﬀort to minimise the number of animals used and promote their
comfort and well-being. The experiments complied with the U.S.
National Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 80-23, revised in 1996) and
were approved by the Committee for Animal Experiments at the
Kawasaki Medical School’s Advanced Research Center. Each animal
was subjected to experimental manipulations only once (n= 7–10 an-
imals per group).
2.2. Reagents
(+)-MK-801 (130-17381, FUJIFILM Wako Pure Chemical
Corporation, Osaka, Japan) was diluted in saline to a concentration of
0.1 mg/mL and administered intraperitoneally at a dose of 0.2mg/kg.
This dose was selected on the basis of previous studies showing schi-
zophrenia-like behaviours in mice following intraperitoneal injections
of MK-801 at 0.2 mg/kg [18–20]. Pentobarbital (Somnopentyl, Kyoritsu
Seiyaku, Tokyo, Japan) was diluted in saline to a concentration of
15mg/mL and administered intraperitoneally at a dose of 30mg/kg.
Scopolamine (S0021, Tokyo Chemical Industry Company, Tokyo,
Japan) was diluted in saline to a concentration of 1mg/mL and ad-
ministered intraperitoneally at a dose of 2mg/kg. Imipramine (097-
06491, FUJIFILM Wako Pure Chemical Corporation) was diluted in
saline to a concentration of 5mg/mL and administered in-
traperitoneally at a dose of 20mg/kg. Although these drugs are not
structural analogues, they all act on the CNS. However, no previous
study has investigated whether these drugs can reach the brain and
exert their eﬀects after inhalational administration.
2.3. Inhalation of reagents
The inhalation apparatus was similar to that used in a previous
study [21]. Mice were exposed to each reagent with a mesh nebuliser
(NEB-01, CUSTOM Corporation, Tokyo, Japan). Inhalation of the re-
agent was carried out in a sealed container. The nebuliser was placed on
a stainless steel wire lid on a new breeding cage (235mm×325
mm×170mm) surrounded by an outer container made with parts
from larger cages (292mm×440mm×200mm) (Fig. 1A). The mice
were unable to lick the reagents. Approximately 5min after nebuliser
placement, the mice were placed in the internal cage for 30min.
2.4. Behavioural tests
All behavioural experiments were performed during the light phase
(9:00–16:00). We tested the mice in random order. After testing, the
apparatus was cleaned with 70% ethanol and with water containing
super-oxidised hypochlorous acid to prevent any bias due to olfactory
cues.
2.5. Locomotor activity test
For measurements of locomotor activity, the mice were acclimated
to the single housing environment. Locomotor activity data were
measured using a photobeam activity system (ACTIMO-100, BRC
Company, Nagoya, Japan), and activity counts were recorded at 10-min
intervals.
2.6. Eﬀects of inhaled MK-801 on mouse locomotor activity
The mice were randomly divided into three groups (n= 10 for each
group) and treated with MK-801 at 0.2mg/kg (intraperitoneal route),
0.1 mg/mL of MK-801 (inhalation), or saline (inhalation) 30min before
the behavioural test. Before measurement of locomotor activity, the
mice were acclimated to the single housing environment for 120min.
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2.7. Eﬀects of MK-801 on mouse locomotor activity following
administration via diﬀerent routes
The mice were randomly divided into four groups and treated with
0.4 mg/kg of MK-801 (oral; n= 9), 0.1 mg/mL of MK-801 (inhalation;
n=6), 0.2mg/kg of MK-801 (intraperitoneal route; n= 9), or saline
(inhalation; n=7) at the start of the behavioural test. Before mea-
surement of locomotor activity, the mice were acclimated to the single
housing environment for 180min.
2.8. Time-dependent eﬀect of MK-801 inhalation on mouse locomotor
activity
The mice were randomly divided into four groups and inhaled
0.1 mg/mL of MK-801 for 0min (n= 7), 10min (n= 10), 30min
(n=10), or 60min (n=10) before the behavioural test. Before mea-
surement of locomotor activity, the mice were acclimated to the single
housing environment for 180min.
2.9. Dose-dependent eﬀect of MK-801 inhalation on mouse locomotor
activity
The mice were randomly divided into four groups and inhaled MK-
801 at 0.05mg/mL (n= 8), 0.10mg/mL (n= 8), or 0.30mg/kg
(n=8) or saline (n=8) 30min before the behavioural test. Before
measurement of locomotor activity, the mice were acclimated to the
single housing environment for 210min.
2.10. Eﬀects of pentobarbital inhalation on mouse locomotor activity
The mice were randomly divided into three groups (n=10 for each
group) and treated with 30mg/kg of pentobarbital (intraperitoneal
route), 15mg/mL of pentobarbital (inhalation), or saline (inhalation)
30min before the behavioural test. Before measurement of locomotor
activity, the mice were acclimated to the single housing environment
for 120min.
2.11. Eﬀects of scopolamine inhalation on mouse locomotor activity
The mice were randomly divided into three groups (n=8 for each
group) and treated with 2mg/kg of scopolamine (intraperitoneal
route), 1 mg/mL of scopolamine (inhalation), or saline (inhalation)
30min before the behavioural test. Before measurement of locomotor
activity, the mice were acclimated to the single housing environment
for 120min.
2.12. Eﬀects of imipramine inhalation on mouse depressive-like behaviour
The mice were randomly divided into three groups (n= 10 for each
group) and treated with 20mg/kg of imipramine (intraperitoneal
route), 5 mg/mL of imipramine (inhalation), or saline (inhalation)
30min before the behavioural test. Each mouse was suspended by the
tail 60 cm above the ﬂoor in a white plastic chamber by using adhesive
tape placed<1 cm from the tip of the tail. Its behaviour was recorded
for 6min. Images were captured via a video camera, and immobility
time was measured. In this test, immobility time was deﬁned as the
total time during which the animals stopped struggling for ≥1 s. Data
acquisition and analysis were performed automatically by using video
tracking software (ANY-MAZE, Stoelting Company, Wood Dale, IL,
USA).
2.13. Statistical analyses of behavioural test results
Data were analysed with two-way analysis of variance (ANOVA)
followed by Tukey’s test or with two-way repeated-measures ANOVA
followed by Fisher’s least signiﬁcant diﬀerence test. A p value of< 0.05
was regarded as statistically signiﬁcant. Data are presented as means
± standard errors or with box plots.
Fig. 1. Inhalation apparatus and the MK-
801–induced eﬀects on locomotion.
(A) The apparatus consisted of a mouse home
cage and an outer container consisting of two
rat cage bases forming a shell. The nebuliser
was placed on a stainless steel wire bar lid on
the home cage. The mouse home cage was
placed inside two larger rat cages. (B)
Spontaneous locomotor activity in each 10-min
period. After 60min, animals were injected
with MK-801 or saline and inhaled MK-801 or
saline. Next, locomotor activity was assessed
for 120min. (C) Number of times a photobeam
was broken during a 50-min period before the
administration of MK-801 or saline and during
the two consecutive 60-min periods im-
mediately after the administration of MK-801
or saline. The “saline (i.p.) + saline (inhala-
tion)” group was treated with saline via the
intraperitoneal and inhalation routes. The
“saline (i.p.) + MK-801 (inhalation)” group
was treated with saline via intraperitoneal ad-
ministration and with MK-801 via inhalation.
The “MK-801 (i.p.) + saline (inhalation)”
group was treated with MK-801 via in-
traperitoneal administration and with saline
via inhalation. Data are presented as means
± standard errors in B and in box plots in C. *,
signiﬁcant diﬀerence between groups
(p < 0.05). The p values were calculated
using two-way repeated-measures analysis of
variance in B and two-way analysis of variance
in C. Abbreviation: i.p., intraperitoneal
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3. Results
3.1. Locomotor activity in mice after MK-801 inhalation
First, we tested the eﬀects of MK-801 inhalation on mouse loco-
motor activity in comparison with the eﬀects after intraperitoneal ad-
ministration of MK-801. Intraperitoneal injection of MK-801 resulted in
a robust increase in locomotor activity, which lasted for a further
120min (Fig. 1B, C Table 1). Inhalation of MK-801 also markedly in-
creased locomotor activity in mice (Fig. 1B). The increased basal ac-
tivity lasted for an additional 120min (Fig. 1B, C). Locomotor activity
counts for the last 60-min period after administration of MK-801 were
signiﬁcantly higher in mice that inhaled MK-801 than in mice that re-
ceived MK-801 injections (Fig. 1B, C).
3.2. Eﬀects of MK-801 on locomotor activity in mice following
administration via diﬀerent routes
We examined whether MK-801 administration aﬀects locomotor
activity in an administration route–dependent manner. A single dose of
MK-801 administered orally to normal mice rapidly increased the lo-
comotor activity, and the increase lasted for a further 120min (Fig. 2A,
B Table 2A, B). Inhalation of MK-801 induced elevated levels of loco-
motor activity in mice. MK-801 gradually increased locomotor activity
30min after the start of inhalation (Fig. 2A, B). MK-801 administered
intraperitonially increased locomotor activity in mice, and the increase
lasted for a further 120min (Fig. 2A, B). Locomotor activity was sig-
niﬁcantly higher in mice that inhaled MK-801 than in mice that re-
ceived MK-801 orally or intraperitonially or that received saline
(Fig. 2A, B).
3.3. Inhalation time–dependency of the locomotor eﬀects of MK-801 in
mice
We examined whether MK-801 inhalation aﬀects locomotor activity
in an inhalation time–dependent manner. The examined MK-801 in-
halation times ranged from 10 to 60min. Inhalation of MK-801 for 30
or 60min induced elevated levels of locomotor activity in mice
(Fig. 3A, B Table 2C, D). Inhalation of MK-801 for 60min markedly
increased the locomotor activity counts in comparison with mice that
inhaled MK-801 for 30min. We observed no signiﬁcant diﬀerence in
Table 1
p values for Fig. 1.
A: Fig. 1B
p value
saline (i.p.) + saline (inhalation) vs saline (i.p.) + MK-801
(inhalation)
0.016
saline (i.p.) + saline (inhalation) vs MK-801 (i.p.) + saline
(inhalation)
< 0.001
saline (i.p.) + MK-801
(inhalation)
vs MK-801 (i.p.) + saline
(inhalation)
0.062
B: Fig. 1C
p value
before 50min
saline (i.p.) + saline (inhalation) vs saline (i.p.) + MK-801 (inhalation) 0.918
saline (i.p.) + saline (inhalation) vs MK-801 (i.p.) + saline (inhalation) 0.588
saline (i.p.) + MK-801 (inhalation) vs MK-801 (i.p.) + saline (inhalation) 0.822
after 60min
saline (i.p.) + saline (inhalation) vs saline (i.p.) + MK-801 (inhalation) < 0.001
saline (i.p.) + saline (inhalation) vs MK-801 (i.p.) + saline (inhalation) < 0.001
saline (i.p.) + MK-801 (inhalation) vs MK-801 (i.p.) + saline (inhalation) 0.259
after 60-120min
saline (i.p.) + saline (inhalation) vs saline (i.p.) + MK-801 (inhalation) < 0.001
saline (i.p.) + saline (inhalation) vs MK-801 (i.p.) + saline (inhalation) 0.005
saline (i.p.) + MK-801 (inhalation) vs MK-801 (i.p.) + saline (inhalation) 0.046
Fig. 2. Eﬀects of MK-801 on locomotor activity following administration via
diﬀerent routes.
(A) Spontaneous locomotor activity was assessed in each 10-min period fol-
lowing MK-801 administration via diﬀerent routes (oral, inhaled, and in-
traperitoneal administration of MK-801 and inhalation of saline) for 180min in
the locomotor activity test. (B) Number of times a photobeam was broken
during three consecutive 60-min periods immediately after the administration
of MK-801 or saline. *, signiﬁcant diﬀerences among groups (p < 0.05). The p
values were calculated by using two-way repeated-measures analysis of var-
iance in A and two-way analysis of variance in B. Abbreviation: i.p., in-
traperitoneal
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the locomotor activity counts between mice exposed to MK-801 for
10min and mice that were not exposed to MK-801 (Fig. 3A, B).
3.4. Inhalation dose–dependency of the locomotor eﬀects of MK-801 in
mice
We examined whether MK-801 inhalation aﬀects locomotor activity
in a dose-dependent manner. The examined MK-801 doses ranged from
0.05 to 0.30mg/kg. Mice that inhaled MK-801 at 0.05mg/kg did not
show increased locomotor activity (Fig. 4A, B Table 2E, F). Inhaling
MK-801 at 10mg/kg resulted in an increase in locomotor activity,
which lasted for a further 60min (Fig. 4A, B). Mice that inhaled MK-
801 at 0.30mg/kg showed increased locomotor activity, which lasted
for a further 210min (Fig. 4A, B).
3.5. Inhalation eﬀects of pentobarbital or scopolamine on locomotor activity
in mice
Next, we examined how the choice of inhalational or intraperitoneal
administration aﬀected the inﬂuence of scopolamine and pentobarbital
on locomotor activity in mice. A previous study indicated that sub-
hypnotic doses of pentobarbital signiﬁcantly increased locomotor ac-
tivity measured for 30min in mice [22]. Administration of scopolamine
has also been shown to markedly increase locomotor activity in mice
[23,24]. Intraperitoneal pentobarbital injections resulted in robust de-
creases in locomotor activity that were consistent with a sub-hypnotic
eﬀect (Fig. 5A, B Table 3A, B). Inhalation of pentobarbital produced a
marked increase in locomotor activity that persisted for 20min
(Fig. 5A, B). Intraperitoneal injection with scopolamine did not result in
an increase in locomotor activity (Fig. 5C, D Table 3C, D). Inhalation of
scopolamine produced a marked increase in locomotor activity (Fig. 5C,
D), which lasted for a further 120min.
Table 2
p values for Fig. 2, 3 and 4.
A: Fig. 2A C: Fig. 3A E: Fig. 4A
p value p value p value
intact vs oral 1 control vs 10min 1 saline vs 0.05mg/ml 1
intact vs inhalation 1 control vs 30min 0.228 saline vs 0.10mg/ml 0.02
intact vs i.p. 0.398 control vs 60min < 0.001 saline vs 0.30mg/ml < 0.001
oral vs inhalation 0.315 10min vs 30min 0.044 0.05mg/ml vs 0.10mg/ml 0.082
oral vs i.p. 1 10min vs 60min < 0.001 0.05mg/ml vs 0.30mg/ml < 0.001
inhalation vs i.p. 0.04 30min vs 60min 0.003 0.10mg/ml vs 0.30mg/ml < 0.001
B: Fig. 2B D: Fig. 3B F: Fig. 4B
p value p value p value
0-60min 0-60min 0-60min
intact vs oral 0.363 control vs 10min 0.938 saline vs 0.05mg/ml 0.884
intact vs inhalation 0.77 control vs 30min 0.007 saline vs 0.10mg/ml 0.006
intact vs i.p. 0.652 control vs 60min < 0.001 saline vs 0.30mg/ml 0.023
oral vs inhalation 0.948 10min vs 30min 0.001 0.05mg/ml vs 0.10mg/ml 0.037
oral vs i.p. 0.957 10min vs 60min < 0.001 0.05mg/ml vs 0.30mg/ml 0.113
inhalation vs i.p. 1 30min vs 60min < 0.001 0.10mg/ml vs 0.30mg/ml 0.954
60-120min 60-120min 60-120min
intact vs oral 0.311 control vs 10min 1 saline vs 0.05mg/ml 1
intact vs inhalation 0.002 control vs 30min 0.263 saline vs 0.10mg/ml 0.679
intact vs i.p. 0.784 control vs 60min < 0.001 saline vs 0.30mg/ml < 0.001
oral vs inhalation 0.065 10min vs 30min 0.176 0.05mg/ml vs 0.10mg/ml 0.704
oral vs i.p. 0.83 10min vs 60min < 0.001 0.05mg/ml vs 0.30mg/ml < 0.001
inhalation vs i.p. 0.011 30min vs 60min < 0.001 0.10mg/ml vs 0.30mg/ml < 0.001
120-180min 120-180min 120-180min
intact vs oral 0.336 control vs 10min 0.999 saline vs 0.05mg/ml 1
intact vs inhalation 0.092 control vs 30min 0.727 saline vs 0.10mg/ml 1
intact vs i.p. 0.926 control vs 60min 0.615 saline vs 0.30mg/ml < 0.001
oral vs inhalation 0.793 10min vs 30min 0.63 0.05mg/ml vs 0.10mg/ml 1
oral vs i.p. 0.674 10min vs 60min 0.48 0.05mg/ml vs 0.30mg/ml < 0.001
inhalation vs i.p. 0.237 30min vs 60min 0.995 0.10mg/ml vs 0.30mg/ml < 0.001
Fig. 3. Inhalation time–dependent nature of MK-801–induced locomotion.
(A) Spontaneous locomotor activity was assessed in each 10-min period fol-
lowing diﬀerent durations of MK-801 inhalation (0, 10, 30, and 60min) for
180min in the locomotor activity test. (B) Number of times a photobeam was
broken during three consecutive 60-min periods immediately after the admin-
istration of MK-801. *, signiﬁcant diﬀerences among groups (p < 0.05). The p
values were calculated using two-way repeated-measures analysis of variance in
A and two-way analysis of variance in B.
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3.6. Inhalation eﬀects of imipramine on depressive-like behaviour in mice
We also examined how the choice of inhalational or intraperitoneal
administration aﬀected the inﬂuence of the antidepressant imipramine
on depressive-like behaviour in mice. In the tail-suspension test, mice
intraperitoneally administered with imipramine were signiﬁcantly less
immobile than mice that received only saline (Fig. 5E, F Table 3E, F).
Thus, inhalation with imipramine resulted in a reduction in immobility
time (Fig. 5E, F). No diﬀerences were observed in immobility between
mice intraperitoneally administered with imipramine and those that
inhaled imipramine.
4. Discussion
In this study, we show that structurally diverse CNS agents can af-
fect mouse behaviour following inhalation. In particular, the ﬁndings
show that inhalation of MK-801 increased the activity levels of mice as
much as intraperitoneal and oral administration did. The ﬁndings of
this study will facilitate the development of new inhalation-based
therapeutic methods for CNS agonists, establishment of new animal
testing methods, and drug management of CNS agonists.
We evaluated the formulation of behavioural (spontaneous motor)
responses via diﬀerent administration routes of MK-801 to mice. We
showed that mice that inhaled MK-801 showed increased activity si-
milar to that observed with intraperitoneal and oral administration.
MK-801 is a non-competitive antagonist of NMDA receptors that are
abundantly distributed in the CNS [25,26]. Consistent with all other
pharmacological agents that induce locomotor sensitisation, MK-801
has been reported to be associated with enhanced dopamine release in
the nucleus accumbens [27]. The results show that MK-801 reached the
CNS of mice following inhalation and aﬀected the behaviour of mice.
Although a mouse could lick or drink MK-801 sprayed by the nebuliser,
the inhalation exposure periods were too short for a mouse to drink or
lick an amount of MK-801 greater than what it would receive under oral
administration conditions. Moreover, inhalation of MK-801 for 10min
did not aﬀect the activity of mice, but inhalation for more than 30min
increased their activity levels. Inhalation of MK-801 for 60min further
increased mouse activity. This suggests that the amount of MK-801
reaching the brain increases depending on the inhalation time.
In experiments with intraperitoneal administration of MK-801, the
administered dose has been known to change the behaviour of mice
[28,29]. In this experimental method, mouse behaviour was aﬀected
when the dose of inhaled MK-801 was 0.1 mg/kg or greater. Further-
more, when the dose of MK-801 increased further, the activity levels of
the mice increased. The results show that MK-801 acts on the mouse
brain and that administration via inhalation is as eﬀective as in-
traperitoneal administration. This result is also consistent with the fact
that drug levels in the blood diﬀer according to the dose and the in-
halation time for inhalation anaesthetics and bronchial drugs [30,31].
We have shown similar ﬁndings for the eﬀects of scopolamine,
pentobarbital, and imipramine on mice. To the best of our knowledge,
there are no reports showing the eﬀects of inhalation of the CNS ago-
nists used in this study. The results of these experiments show that the
behavioural changes induced by MK-801 inhalation are not due to
chance and that it is possible that CNS agonists are eﬃciently trans-
ferred to the brain following inhalation.
Further studies are needed to determine the details underlying the
access to the brain observed in this study. The possible pathways in-
clude (1) a route to reach the brain from the nasal cavity via the ol-
factory nerve pathway and the trigeminal nerve pathway, (2) absorp-
tion into the bloodstream from the nasal cavity and permeation into the
BBB, and (3) uptake from respiratory system pathways and absorption
into the bloodstream. Future studies should use radiolabelling to in-
vestigate this issue by tracing the distribution of MK-801 in brain tissue
following intranasal administration.
Studies have suggested that the intranasal route can deliver drugs
directly from the nasal cavity along the olfactory and trigeminal nerves
to the brain [32]. For example, a study in which rats received halo-
peridol via intranasal administration found that haloperidol was un-
detectable in plasma collected shortly after haloperidol dosing [33].
This ﬁnding suggests that haloperidol was transported directly from the
nasal cavity to the brain without any absorption into circulating blood.
In recent studies supporting nose-to-brain transport along the olfactory
and trigeminal nerves, it has been shown that substances are rapidly
transported into the brain and/or brainstem through associations with
neuroﬁlaments present along neuroanatomical processes [34,35].
Intranasal delivery is distinctive among the various strategies cur-
rently available for drug targeting. In fact, intranasal administration has
been attempted for various therapeutic agents, including sumatriptan
for migraine headaches, desmopressin for the treatment of diabetes
mellitus in response to lactation, oxytocin for breast milk secretion, and
the dopaminergic agonist apomorphine to accelerate childbirth
[36,37]. Currently, nasal administration requires that the use of a
dedicated device for administering a drug solution [38,39]. In this
study, we showed that MK-801 can exert eﬀects on the brain following
aromatherapy-style inhalation without the use of a dedicated device.
Administration of a therapeutic drug via inhalation is expected to be
useful for various patient groups, such as patients with dementia and
patients with post-operative delirium, which can make it diﬃcult to
take medicines. The results of this study suggest that the administration
of drugs by inhalation is an attractive option for delivering drugs to the
brain and that delivery by inhalation is superior to other options for
delivering drugs to the brain. Our ﬁndings have particularly compelling
implications for experiments with mice, for which intraperitoneal in-
jections are potentially stressful due to the invasive nature of the in-
jections and the need for handling by the experimenter. Our results
suggest that intraperitoneal injections can be replaced with drug in-
halation to reduce the stress levels in mice. Our research results will
Fig. 4. Dose-dependent nature of MK-801–induced locomotion.
(A) Spontaneous locomotor activity was assessed in each 10-min period fol-
lowing diﬀerent doses of MK-801 inhalation (0.05, 0.10, and 0.30mg/mL) for
210min in the locomotor activity test. (B) “Number of times a photobeam was
broken during three consecutive 60-min periods immediately after the admin-
istration of MK-801 or saline. *, signiﬁcant diﬀerences among groups
(p < 0.05). The p values were calculated using two-way repeated measures
analysis of variance in A and two-way analysis of variance in B.
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also facilitate the establishment of new experimental methods.
This study shows that chemical substances act on the CNS by in-
halation. However, researchers and many other people may inhale
volatilised chemical solutions. Thus, this study shows the necessity of
properly managing chemicals to promote safe laboratory working
conditions.
In many studies, fragrant compounds have been shown to be cap-
able of crossing the BBB and interacting with CNS receptors, so fra-
grance inhalation has a major impact on brain function [40,41]. When
essential oils are inhaled into the nasal cavity, aerosolised molecules
attach to the cilia of olfactory receptors lining the olfactory epithelium
[42,43]. The results of these experiments also address one aspect of the
mechanisms underlying the eﬀects of inhalation of essential oils.
5. Conclusions
This study showed that inhalation of the CNS agonists MK-801,
pentobarbital, scopolamine, and imipramine had eﬀects on the CNS in
mice and inﬂuenced their behaviour. Although the pathway by which
drugs reach the brain after inhalation remains unclear, this study’s
Fig. 5. Induction of locomotion with pento-
barbital and scopolamine and depressive-like
behaviours with imipramine.
(A) Spontaneous pentobarbital-induced loco-
motor activity was assessed in each 10-min
period. After 50min, animals were injected
with pentobarbital or saline and inhaled pen-
tobarbital or saline. Next, locomotor activity
was assessed for 120min. (B) Number of times
a photobeam was broken during a 50-min
period before the administration of pento-
barbital or saline, during the ﬁrst 20min after
the administration of pentobarbital or saline,
and during the period 20–120 after the ad-
ministration of pentobarbital or saline. The
“saline (i.p.) + saline (inhalation)” group was
treated with saline via the intraperitoneal and
inhalation routes. The “saline (i.p.) + pento-
barbital (inhalation)” group was treated with
saline via intraperitoneal administration and
with pentobarbital via inhalation. The “pento-
barbital (i.p.) + saline (inhalation)” group was
treated with pentobarbital via intraperitoneal
administration and with saline via inhalation.
(C) Spontaneous scopolamine-induced loco-
motor activity was assessed in each 10-min
period. After 50min, animals were injected
with scopolamine or saline and inhaled sco-
polamine or saline. Next, locomotor activity
was assessed for 120min. (D) Number of times
a photobeam was broken during a 50-min
period before the administration of scopola-
mine or saline and during the two consecutive
60-min periods immediately after the admin-
istration of scopolamine or saline. The “saline
(i.p.) + saline (inhalation)” group was treated
with saline via the intraperitoneal and inhala-
tion routes. The “saline (i.p.) + scopolamine
(inhalation)” group was treated with saline via
intraperitoneal administration and with sco-
polamine via inhalation. The “scopolamine
(i.p.) + saline (inhalation)” group was treated
with scopolamine via intraperitoneal adminis-
tration and with saline via inhalation. (E)
Mean proportion of time spent immobile in
each 1-min period following imipramine vapor
inhalation for 30min in the tail-suspension
test. (F) Total immobility times The “saline
(i.p.) + saline (inhalation)” group was treated
with saline via the intraperitoneal and inhala-
tion routes. The “saline (i.p.) + imipramine
(inhalation)” group was treated with saline via
intraperitoneal administration and with imi-
pramine via inhalation. The “imipramine (i.p.)
+ saline (inhalation)” group was treated with
imipramine via intraperitoneal administration
and with saline via inhalation. Data are presented as means ± standard errors in A, C, and E and in box plots in B, D, and F. *, signiﬁcant diﬀerences among groups
(p < 0.05). The p values were calculated using two-way repeated measures analysis of variance in A, C, and E and two-way analysis of variance in B, D, and F.
Abbreviation: i.p., intraperitoneal
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ﬁndings suggest that intranasal administration techniques can facilitate
the development of new therapeutic strategies for CNS disorders.
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Table 3
p values for Fig. 5.
A: Fig. 5A
p value
saline (i.p.) + saline (inhalation) vs saline (i.p.) + pentobarbital (inhalation) 1
saline (i.p.) + saline (inhalation) vs pentobarbital (i.p.) + saline (inhalation) 0.704
saline (i.p.) + pentobarbital (inhalation) vs pentobarbital (i.p.) + saline (inhalation) 1
B: Fig. 5B
p value
before 50min
saline (i.p.) + saline (inhalation) vs saline (i.p.) + pentobarbital (inhalation) 0.628
saline (i.p.) + saline (inhalation) vs pentobarbital (i.p.) + saline (inhalation) 0.962
saline (i.p.) + pentobarbital (inhalation) vs pentobarbital (i.p.) + saline (inhalation) 0.876
after 20min
saline (i.p.) + saline (inhalation) vs saline (i.p.) + pentobarbital (inhalation) 0.043
saline (i.p.) + saline (inhalation) vs pentobarbital (i.p.) + saline (inhalation) 0.438
saline (i.p.) + pentobarbital (inhalation) vs pentobarbital (i.p.) + saline (inhalation) 0.009
after 20-120min
saline (i.p.) + saline (inhalation) vs saline (i.p.) + pentobarbital (inhalation) 0.868
saline (i.p.) + saline (inhalation) vs pentobarbital (i.p.) + saline (inhalation) 0.767
saline (i.p.) + pentobarbital (inhalation) vs pentobarbital (i.p.) + saline (inhalation) 0.957
C: Fig. 5C
p value
saline (i.p.) + saline (inhalation) vs saline (i.p.) + scopolamine (inhalation) 0.002
saline (i.p.) + saline (inhalation) vs scopolamine (i.p.) + saline (inhalation) 0.05
saline (i.p.) + scopolamine (inhalation) vs scopolamine (i.p.) + saline (inhalation) 1
D: Fig. 5D
p value
before 50min
saline (i.p.) + saline (inhalation) vs saline (i.p.) + scopolamine (inhalation) 0.984
saline (i.p.) + saline (inhalation) vs scopolamine (i.p.) + saline (inhalation) 0.998
saline (i.p.) + scopolamine (inhalation) vs scopolamine (i.p.) + saline (inhalation) 0.993
after 60min
saline (i.p.) + saline (inhalation) vs saline (i.p.) + scopolamine (inhalation) 0.003
saline (i.p.) + saline (inhalation) vs scopolamine (i.p.) + saline (inhalation) 0.966
saline (i.p.) + scopolamine (inhalation) vs scopolamine (i.p.) + saline (inhalation) 0.005
after 60-120min
saline (i.p.) + saline (inhalation) vs saline (i.p.) + scopolamine (inhalation) 0.048
saline (i.p.) + saline (inhalation) vs scopolamine (i.p.) + saline (inhalation) 0.658
saline (i.p.) + scopolamine (inhalation) vs scopolamine (i.p.) + saline (inhalation) 0.005
E: Fig. 5E
p value
saline (i.p.) + saline (inhalation) vs saline (i.p.) + imipramine (inhalation) 0.042
saline (i.p.) + saline (inhalation) vs imipramine (i.p.) + saline (inhalation) 0.043
saline (i.p.) + imipramine (inhalation) vs imipramine (i.p.) + saline (inhalation) 1
F: Fig. 5F
p value
saline (i.p.) + saline (inhalation) vs saline (i.p.) + imipramine (inhalation) 0.038
saline (i.p.) + saline (inhalation) vs imipramine (i.p.) + saline (inhalation) 0.039
saline (i.p.) + imipramine (inhalation) vs imipramine (i.p.) + saline (inhalation) 0.639
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